0001209191-18-015100.txt : 20180301 0001209191-18-015100.hdr.sgml : 20180301 20180301171049 ACCESSION NUMBER: 0001209191-18-015100 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180227 FILED AS OF DATE: 20180301 DATE AS OF CHANGE: 20180301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Waldin Jan-Paul CENTRAL INDEX KEY: 0001733176 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37347 FILM NUMBER: 18658788 MAIL ADDRESS: STREET 1: 77 KING STREET WEST STREET 2: SUITE 3000 CITY: TORONTO STATE: A6 ZIP: M5K 1G8 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: XBiotech Inc. CENTRAL INDEX KEY: 0001626878 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8201 E. RIVERSIDE DRIVE STREET 2: BUILDING 4, SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78744 BUSINESS PHONE: 512-386-2930 MAIL ADDRESS: STREET 1: 8201 E. RIVERSIDE DRIVE STREET 2: BUILDING 4, SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78744 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-02-27 0 0001626878 XBiotech Inc. XBIT 0001733176 Waldin Jan-Paul 77 KING STREET WEST SUITE 3000 TORONTO A6 M5K 1G8 ONTARIO, CANADA 1 0 0 0 Director Stock Option 4.83 2018-02-27 4 A 0 25000 0.00 A 2018-08-27 2028-02-27 Common Stock 25000 25000 D Upon election as a Board Member and pursuant to the Board Member Agreement in place between Jan-Paul Waldin (the "Reporting Person") and the Company (the "Agreement"), the Reporting Person was granted non-qualified stock options to purchase 25,000 shares of the Company's common stock on February 27, 2018 (the "Grant Date"). All granted options will be exercisable at a price equal to the closing price of the Company's common stock, as reported by NASDAQ, on the Grant Date, and vest in two equal installments occurring six months and 12 months following the Grant Date, subject to continued service as a Director. The Options shall expire ten years from the Grant Date, unless terminated earlier in accordance with the Plan or the Reporting Person's stock option agreement. In accordance with the Plan, the Options will remain exercisable for 90 days after the date of the Reporting Person's termination without cause or resignation. /s/ Ashley Otero under Power of Attorney for Jan-Paul Waldin 2018-03-01